By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – PCR technology development company QuantaLife announced late Friday that it had closed on a Series B financing round, raising $17.2 million.

The majority of the funds will be used to create a commercialization operation to launch its Droplet Digital PCR platform for the research market and to accelerate development of targeted diagnostic tests, the Pleasanton, Calif.-based company said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.